Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18996856 | 0.87 | FFAR1 (0.49) | FFAR1IRAK4KLKB1 | |
| SCHEMBL17247588 | 0.83 | FFAR1 (0.52) | FFAR1IRAK4KLKB1 | |
| SCHEMBL15885161 | 0.82 | FFAR1 (0.50) | FFAR1IRAK4KLKB1 | |
| SCHEMBL20401337 | 0.80 | FFAR1 (0.51) | FFAR1IRAK4KLKB1DGAT1 | |
| SCHEMBL15885095 | 0.79 | FFAR1 (0.47) | FFAR1IRAK4KLKB1DGAT1 | |
| SCHEMBL16754201 | 0.76 | FFAR1 (0.44) | FFAR1IRAK4HCRTR1HCRTR2 | |
| SCHEMBL29801233 | 0.76 | FFAR1 (0.44) | FFAR1IRAK4HCRTR1HCRTR2 | |
| SCHEMBL1356885 | 0.76 | FFAR1 (0.51) | FFAR1KLKB1DGAT1 | |
| SCHEMBL22242341 | 0.76 | HCRTR1 (0.40) | ADORA2AADORA2BADORA1HCRTR1HCRTR2 | |
| SCHEMBL29378031 | 0.76 | FFAR1 (0.51) | FFAR1KLKB1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195447-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4310082-A2 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | Arcus Biosciences, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-116768859-A | Azolopyrimidines for the treatment of cancer related disorders | 艾库斯生物科学有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-3570844-B1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3618829-B1 | QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| CN-110214012-B | Azolopyrimidines for the treatment of cancer related disorders | 艾库斯生物科学有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20220144808-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11072597-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. | 2021-07-27 | — | — | US | disclosed |
| US-11045472-B2 | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210101880-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2021-04-08 | — | — | US | disclosed |
| US-20200069689-A1 | QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2020-03-05 | — | — | US | disclosed |
| US-10399962-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
| WO-2018136700-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144808-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | FFAR1 1017/4885ADORA2A 1/4885ADORA2B 2/4885 |
| US-11072597-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ADORA2A, ADORA2B, ADORA1 | FFAR1 1017/4885ADORA2A 1/4885ADORA2B 2/4885 |
| US-12195447-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ADORA2A, ADORA2B, ADORA1 | FFAR1 1017/4885ADORA2A 1/4885ADORA2B 2/4885 |
| US-20200069689-A1 | QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA3 | FFAR1 928/4885ADORA2A 1/4885ADORA2B 2/4885 |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | ADORA2A, ADORA2B, ADORA3 | FFAR1 151/4885ADORA2A 1/4885ADORA2B 2/4885 |
| US-11045472-B2 | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | ADORA2A, ADORA2B, ADORA1 | FFAR1 751/4885ADORA2A 1/4885ADORA2B 2/4885 |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | FFAR1 1017/4885ADORA2A 1/4885ADORA2B 2/4885 |
| US-10399962-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ADORA2A, ADORA2B, ADORA1 | FFAR1 1017/4885ADORA2A 1/4885ADORA2B 2/4885 |
| US-20210101880-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | FFAR1 1017/4885ADORA2A 1/4885ADORA2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.